Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cogent Biosciences, Inc. (COGT)

10.11   0.07 (0.7%) 03-24 16:00
Open: 9.94 Pre. Close: 10.04
High: 10.28 Low: 9.935
Volume: 528,552 Market Cap: 707(M)

Technical analysis

as of: 2023-03-24 4:24:59 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 14.19     One year: 16
Support: Support1: 9.64    Support2: 8.02
Resistance: Resistance1: 12.15    Resistance2: 13.69
Pivot: 11.67
Moving Average: MA(5): 10.49     MA(20): 12.03
MA(100): 12.45     MA(250): 11.42
MACD: MACD(12,26): -0.8     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 7.4     %D(3): 4.6
RSI: RSI(14): 31.4
52-week: High: 18.06  Low: 3.78
Average Vol(K): 3-Month: 629 (K)  10-Days: 674 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ COGT ] has closed above bottom band by 10.4%. Bollinger Bands are 49.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.3 - 10.37 10.37 - 10.43
Low: 9.77 - 9.85 9.85 - 9.93
Close: 9.98 - 10.11 10.11 - 10.24

Company Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 24 Mar 2023
Assenagon Asset Management S.A. Has $8.07 Million Position in ... - MarketBeat

Fri, 17 Mar 2023
Cogent Biosciences, Inc. (NASDAQ:COGT) Forecasted to Post ... - MarketBeat

Tue, 14 Mar 2023
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results - Yahoo Finance

Fri, 03 Mar 2023
MetLife Investment Management LLC increases its stake in Cogent ... - Best Stocks

Thu, 23 Feb 2023
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by ... - MarketBeat

Thu, 09 Feb 2023
Janus Henderson Group Cuts Stake in Cogent Biosciences (COGT) - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 70 (M)
Shares Float 52 (M)
% Held by Insiders 0 (%)
% Held by Institutions 111 (%)
Shares Short 5,540 (K)
Shares Short P.Month 4,980 (K)

Stock Financials

EPS -2.19
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.72
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -34.7
Return on Equity (ttm) -59.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) -1.74
Sales Per Share 0
EBITDA (p.s.) -2.11
Qtrly Earnings Growth 0
Operating Cash Flow -119 (M)
Levered Free Cash Flow -67 (M)

Stock Valuations

PE Ratio -4.64
PEG Ratio 0
Price to Book value 3.71
Price to Sales 0
Price to Cash Flow -5.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-11-08
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.